Cure My Disease

Don't miss your cure!

 Log in / Sign up

Finding the best pill form: a drug for COVID-19 complications gets a formulation check

NCT ID NCT04656288

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial studies how the drug BI 764198 is absorbed into the body when given as different pill types (capsules vs. tablets) and with or without food. It involves 28 healthy adults aged 18 to 50. The goal is to find the best oral formulation for future use in patients hospitalized with COVID-19 who are at risk of respiratory complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BI 764198 (Apecotrep)
What this could lead to
If successful, this trial will identify the best way to take BI 764198, potentially improving its use in future studies for COVID-19 patients at risk of breathing problems.
What could go wrong
This is an early-stage trial in healthy volunteers, not patients. The drug may not work as hoped in sick people, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

  • SGS Belgium NV Research Unit Stuivenberg

    Antwerp, 2060, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.